Literature DB >> 7200547

[Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)].

H W von Heyden, H Henkel, G A Nagel, N Weinstock.   

Abstract

Concentrations of platin were determined with the method of atomic absorption spectroscopy in plasma and urine from the 1st until 28th day after cis-DDP (3 mg/kg) infusion for 1, 8, and 24 h. Maximum of plasma concentration was measured always at the end of the application time. Minimal concentration was 1.9 micrograms/ml, maximal concentration 5.8 micrograms/ml. Platin could be detected until the 21st respectively 28th day between 0.01 and 0.9 micrograms/ml. The duration of cis-DDP infusions was without influence on the mean excretion of platin. Between 24 and 25% of the infused platin was excreted after 24 h, between 4.8 and 7% after further 24 h, between 1 and 2% between the 3rd and 21st day, and less than 1% thereafter. Difference in pattern of toxicity could not be clearly detected.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200547     DOI: 10.1007/bf01728344

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

Review 1.  Mechanism of action of cis-dichlorodiammineplatinum(II).

Authors:  L A Zwelling; K W Kohn
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

2.  Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

Authors:  R C DeConti; B R Toftness; R C Lange; W A Creasey
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

3.  Distribution of cis-platin in blood.

Authors:  R C Manaka; W Wolf
Journal:  Chem Biol Interact       Date:  1978-09       Impact factor: 5.192

4.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

Authors:  T F Patton; K J Himmelstein; R Belt; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1978-09

5.  Quantitative changes in cis-dichlorodiammineplatinum(II) speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results.

Authors:  A F LeRoy; M Wehling; P Gormley; M Egorin; S Ostrow; N Bachur; P Wiernik
Journal:  Cancer Treat Rep       Date:  1980-01

Review 6.  [Cis-diamminedichloroplatinum(II). A new antineoplastic agent derived from the group of heavy metal complexes (author's transl)].

Authors:  R Osieka; C G Schmidt
Journal:  Klin Wochenschr       Date:  1979-12-03

7.  Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.

Authors:  D A Ross; G R Gale
Journal:  Cancer Treat Rep       Date:  1979-05

8.  Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).

Authors:  R J Belt; K J Himmelstein; T F Patton; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

9.  Acute renal failure after cis-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies.

Authors:  J C Gonzalez-Vitale; D M Hayes; E Cvitkovic; S S Sternberg
Journal:  Cancer Treat Rep       Date:  1978-05

10.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

View more
  1 in total

1.  Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; R Morris; S Freeman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.